Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 68% Improvement Relative Risk Ventilation 66% c19early.org/d Hurst et al. Vitamin D for COVID-19 Sufficiency Favors vitamin D Favors control
Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study
Hurst et al., BMJ Open, doi:10.1136/bmjopen-2021-055435
Hurst et al., Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study, BMJ Open, doi:10.1136/bmjopen-2021-055435
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of 259 hospitalized COVID-19 patients in the UK, showing a majority of patients had vitamin D deficiency/insufficiency, which was associated with poor outcomes. Both free and total 25(OH)D were analyzed with consistent results. ISRCTN66726260.
risk of death, 68.4% lower, RR 0.32, p = 0.005, high D levels 68, low D levels 191, odds ratio converted to relative risk, >50nmol/l, multivariable, Supplementary Table 2, control prevalance approximated with overall prevalence.
risk of mechanical ventilation, 66.0% lower, RR 0.34, p = 0.004, high D levels 6 of 68 (8.8%), low D levels 61 of 191 (31.9%), NNT 4.3, odds ratio converted to relative risk, >50nmol/l, multivariable, Supplementary Table 2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hurst et al., 22 Oct 2021, prospective, United Kingdom, peer-reviewed, 23 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Open access Original research Emma A Hurst,1,2 Richard J Mellanby,1 Ian Handel,1 David M Griffith ‍ ‍,3 Adriano G Rossi,4 Timothy S Walsh,4,5 Manu Shankar-­Hari,6,7 Jake Dunning,8 Natalie Z Homer,2 Scott G Denham,2 Kerri Devine,2 Paul A Holloway,9 Shona C Moore,10 Ryan S Thwaites,11 Romit J Samanta,12 Charlotte Summers ‍ ‍,12 Hayley E Hardwick,10 Wilna Oosthuyzen,13 Lance Turtle,10,14 Malcolm G Semple,10,15 Peter J M Openshaw,11 J Kenneth Baillie,5,13 Clark D Russell ‍ ‍,4,13 ISARIC4C Investigators To cite: Hurst EA, Mellanby RJ, Handel I, et al. Vitamin D insufficiency in COVID-­19 and influenza A, and critical illness survivors: a cross-­ sectional study. BMJ Open 2021;11:e055435. doi:10.1136/ bmjopen-2021-055435 ►► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://​dx.​doi.o​ rg/​10.​1136/​ bmjopen-​2021-​055435). Received 13 July 2021 Accepted 30 September 2021 © Author(s) (or their employer(s)) 2021. Re-­use permitted under CC BY. Published by BMJ. For numbered affiliations see end of article. Correspondence to Dr Clark D Russell; ​clark.​russell@e​ d.​ac.​uk ABSTRACT Objectives The steroid hormone vitamin D has roles in immunomodulation and bone health. Insufficiency is associated with susceptibility to respiratory infections. We report 25-­hydroxy vitamin D (25(OH)D) measurements in hospitalised people with COVID-­19 and influenza A and in survivors of critical illness to test the hypotheses that vitamin D insufficiency scales with illness severity and persists in survivors. Design Cross-­sectional study. Setting and participants Plasma was obtained from 295 hospitalised people with COVID-­19 (International Severe Acute Respiratory and emerging Infections Consortium (ISARIC)/WHO Clinical Characterization Protocol for Severe Emerging Infections UK study), 93 with influenza A (Mechanisms of Severe Acute Influenza Consortium (MOSAIC) study, during the 2009–2010 H1N1 pandemic) and 139 survivors of non-­selected critical illness (prior to the COVID-­19 pandemic). Total 25(OH)D was measured by liquid chromatography-­tandem mass spectrometry. Free 25(OH)D was measured by ELISA in COVID-­19 samples. Outcome measures Receipt of invasive mechanical ventilation (IMV) and in-­hospital mortality. Results Vitamin D insufficiency (total 25(OH)D 25– 50 nmol/L) and deficiency (<25 nmol/L) were prevalent in COVID-­19 (29.3% and 44.4%, respectively), influenza A (47.3% and 37.6%) and critical illness survivors (30.2% and 56.8%). In COVID-­19 and influenza A, total 25(OH) D measured early in illness was lower in patients who received IMV (19.6 vs 31.9 nmol/L (p<0.0001) and 22.9 vs 31.1 nmol/L (p=0.0009), respectively). In COVID-­19, biologically active free 25(OH)D correlated with total 25(OH)D and was lower in patients who received IMV, but was not associated with selected circulating inflammatory mediators. Conclusions Vitamin D deficiency/insufficiency was present in majority of hospitalised patients with COVID-­19 or influenza A and correlated with severity and persisted in critical illness survivors at concentrations expected to disrupt bone metabolism. These findings support early supplementation trials to determine if insufficiency is Strengths and limitations of this study ►► Liquid chromatography-­tandem mass spectrometry was used to quantify 25-­hydroxy vitamin D (25(OH) D) in plasma samples from well-­characterised..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit